2 results
Approved WMOWill not start
PRIMARY• To determine the efficacy on study Day 28 of the IT-combination in inducing a clinical response in patients with severe acute GVHD refractory to first line therapy with intermediate dose corticosteroids. SECONDARY• To evaluate the overall…
Approved WMOCompleted
The primary efficacy objective of the study is:* to evaluate whether rivaroxaban added to ASA is superior to ASA alone in reducingthe risk of major thrombotic vascular events (defined as MI, ischemic stroke, CVdeath, ALI, and major amputation of a…